Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Biotech to Test Stem Cell Product in COVID-19-Caused Acute Respiratory Distress

A description of Mesoblast's multi-site clinical trial and possible implication for the therapeutic are provided in an H.C. Wainwright & Co. report. In an April 9 research note, H.C. Wainwright & Co. analyst Swayampakula Ramakanth reported that Mesoblast Lt...
Streetwise Reports | April 16, 2020 |

Interim Data Indicate Multiantigen Cell Therapy in Solid Tumors 'Just Might Work'

The immuno-oncology company's findings are reviewed in a ROTH Capital Partners report. In a July 22 research note, ROTH Capital Partners analyst Tony Butler reported that "encouraging data" from Marker Therapeutics Inc.'s (MRKR:NASDAQ) Phase I trial, TACTO...
Streetwise Reports | July 24, 2019 |

Precision Medicine Firm Announces 'Positive' Data in Lymphoma Study

The highlights of the results were presented in an H.C. Wainwright & Co. report. In a June 14 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported that Kura Oncology Inc. (KURA:NASDAQ) met the endpoint in its Phase 2 clinical trial of...
Streetwise Reports | June 21, 2019 |

Coverage Initiated on Cancer Vaccine Firm

An H.C. Wainwright & Co. report explained the reasons for its "bullish view" on this California-based life sciences company. In a March 7 research note, analyst Swayampakula Ramakanth reported that H.C. Wainwright & Co. initiated coverage on Gritstone Oncology Inc. (GR...
Streetwise Reports | March 11, 2019 |

Analyst Believes Biopharma's Alzheimer's Treatment Could Be Superior to Biogen's

How this company's Alzheimer's therapeutic compares to an advanced-stage competitor is outlined in a Dawson James Securities note. In a Dec. 2 research note, Dawson James Securities analyst Jason Kolbert purported that Anavex Life Sciences Corp.'s (AVXL:NASDAQ) ANAV...
Streetwise Reports | December 11, 2019 |

Biotech to Test Stem Cell Product in COVID-19-Caused Acute Respiratory Distress

A description of Mesoblast's multi-site clinical trial and possible implication for the therapeutic are provided in an H.C. Wainwright & Co. report.
Streetwise Reports | May 14, 2020 |

Coverage Initiated on Biotech Whose Therapies 'Can Compete with CAR-Ts'

The reasons for the Buy rating on the U.K. firm are delineated in a ROTH Capital Partners report. In a May 30 research note, analyst Tony Butler reported that ROTH Capital Partners initiated coverage on Adaptimmune Therapeutics Plc (ADAP:NASDAQ) with a...
Streetwise Reports | June 10, 2019 |

'Data Readouts Approaching in Two Pivotal Trials' for Biopharma Targeting Unmet Needs

The next steps for each of the programs are outlined in a Dawson James Securities report. In an Aug. 14 research note, Dawson James Securities analyst Jason Kolbert reported that Soligenix Inc. (SNGX:NASDAQ) "is now focused on the two pivotal programs, i...
Streetwise Reports | August 22, 2019 |

'Stay Tuned for Data' from Regenerative Medicine Firm with 'Blockbuster Opportunity'

The compelling aspects of this life sciences story are presented in a Dawson James report. In a Jan. 28 research note, analyst Jason Kolbert reported that Dawson James Securities increased its target price on Mesoblast Ltd. (MESO:NASDAQ; MSB:ASX) to $15 pe...
Streetwise Reports | February 3, 2020 |

Biopharma to Test Immunity Activator in Advanced Solid Cancers

The company's plans for and approach to one of its most advanced drug candidates are discussed in an H.C. Wainwright & Co. report. In a Dec. 12 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that BioXcel Therapeutics Inc. (BTAI:NASDAQ) plans to ...
Streetwise Reports | December 19, 2019 |
1 2 3 4 5 6 7 8 9 10 ...